Is JPM worth it? As the buzzy con­fer­ence dies down, de­bate on its val­ue rum­bles on

The ex­or­bi­tant cost of at­tend­ing JP­Mor­gan — from ho­tels and flights to cof­fee and meet­ing space — has long been a talk­ing point for bio­phar­ma ex­ecs gath­er­ing in San Fran­cis­co every Jan­u­ary. But as the in­dus­try’s sig­na­ture net­work­ing con­fab fades out, the age-old ques­tion is once again in fo­cus: Is it all worth­while?

In a re­flec­tive ar­ti­cle be­moan­ing the con­fer­ence’s val­ue and a neg­a­tive stream of “ex­cess­es,” Bruce Booth of At­las Ven­ture gave an em­phat­ic an­swer: No.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER